Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Peripheral neuropathy (length-dependent polyneuropathy)

Neurology · Symptom or situation · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: 3.4 to 3.7% of people over 55 seen by Italian GPs, 4.2 to 5.3% after 75 [1]

First-line tests (cause not obvious)

Fasting sample.

Fasting laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (8)
  1. Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015;314(20):2172-81.
  2. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, AANEM and AAPM&R. Neurology. 2009;72(2):185-92.
  3. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0570 (protéinogramme), 1571 et 1572 (immunofixation), 1577 (HbA1c).
  4. Haute Autorité de santé. Prise en charge diagnostique des neuropathies périphériques (polyneuropathies et mononeuropathies multiples). Recommandations professionnelles, mai 2007.
  5. Nederlandse Vereniging voor Neurologie (NVN). Richtlijn Polyneuropathie, module « Laboratoriumonderzoek zonder alarmsymptomen bij polyneuropathie », publié le 5 juillet 2019. Richtlijnendatabase, Federatie Medisch Specialisten.
  6. Nederlandse Vereniging voor Neurologie (NVN). Richtlijn Polyneuropathie, module « Laboratoriumonderzoek bij bekende risicofactor van polyneuropathie », 2019. Richtlijnendatabase, Federatie Medisch Specialisten.
  7. Grzych G, Lee GR, Alpdemir M, Gernez E, Anseeuw K, Bjorke-Monsen AL, et al. Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse. Clin Chem Lab Med. 2026;64(4):813-20.
  8. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-83.